347 related articles for article (PubMed ID: 19296412)
41. A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia.
Liapikou A; Polverino E; Cilloniz C; Peyrani P; Ramirez J; Menendez R; Torres A;
Respir Care; 2014 Jul; 59(7):1078-85. PubMed ID: 24194575
[TBL] [Abstract][Full Text] [Related]
42. Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia?
Kelly E; MacRedmond RE; Cullen G; Greene CM; McElvaney NG; O'Neill SJ
Respirology; 2009 Mar; 14(2):210-6. PubMed ID: 19272082
[TBL] [Abstract][Full Text] [Related]
43. Tuberculosis: still overlooked as a cause of community-acquired pneumonia--how not to miss it.
Kunimoto D; Long R
Respir Care Clin N Am; 2005 Mar; 11(1):25-34. PubMed ID: 15763219
[TBL] [Abstract][Full Text] [Related]
44. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
45. Community-acquired pneumonia in children: from diagnosis to treatment.
Greenberg D; Leibovitz E
Chang Gung Med J; 2005 Nov; 28(11):746-52. PubMed ID: 16422179
[TBL] [Abstract][Full Text] [Related]
46. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?
Esposito S; Cohen R; Domingo JD; Pecurariu OF; Greenberg D; Heininger U; Knuf M; Lutsar I; Principi N; Rodrigues F; Sharland M; Spoulou V; Syrogiannopoulos GA; Usonis V; Vergison A; Schaad UB
Pediatr Infect Dis J; 2012 Jun; 31(6):e78-85. PubMed ID: 22466326
[TBL] [Abstract][Full Text] [Related]
47. Novel targets in the management of pneumonia.
Díaz LA; Mortensen EM; Anzueto A; Restrepo MI
Ther Adv Respir Dis; 2008 Dec; 2(6):387-400. PubMed ID: 19124384
[TBL] [Abstract][Full Text] [Related]
48. Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials.
Mandell LA
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S189-92. PubMed ID: 18986288
[TBL] [Abstract][Full Text] [Related]
49. Management of severe community-acquired pneumonia of children in developing and developed countries.
Principi N; Esposito S
Thorax; 2011 Sep; 66(9):815-22. PubMed ID: 20965930
[TBL] [Abstract][Full Text] [Related]
50. Bacterial aetiology and mortality in COPD patients with CAP: results from the German Competence Network, CAPNETZ.
Braeken DC; Franssen FM; von Baum H; Schütte H; Pletz MW; Rupp J; Stassen F; Mooij MJ; Rohde GG
Int J Tuberc Lung Dis; 2017 Feb; 21(2):236-243. PubMed ID: 28234091
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology and bacteriology of bacterial pneumonias.
Heath PT
Paediatr Respir Rev; 2000 Mar; 1(1):4-7. PubMed ID: 16263435
[TBL] [Abstract][Full Text] [Related]
52. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy.
Viegi G; Pistelli R; Cazzola M; Falcone F; Cerveri I; Rossi A; Ugo Di Maria G
Respir Med; 2006 Jan; 100(1):46-55. PubMed ID: 16046113
[TBL] [Abstract][Full Text] [Related]
53. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
[TBL] [Abstract][Full Text] [Related]
54. Risk factors for community-acquired pneumonia in German adults: the impact of children in the household.
Schnoor M; Klante T; Beckmann M; Robra BP; Welte T; Raspe H; Schäfer T;
Epidemiol Infect; 2007 Nov; 135(8):1389-97. PubMed ID: 17291378
[TBL] [Abstract][Full Text] [Related]
55. Differences between Bedouin and Jewish populations in incidence and characteristics of patients hospitalized with community-acquired pneumonia.
Novack V; Avnon LS; Etzion O; Riesenberg K; Elbaz G; Schlaeffer F
Ethn Dis; 2007; 17(3):441-6. PubMed ID: 17985495
[TBL] [Abstract][Full Text] [Related]
56. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
57. [Critical evaluation and predictive value of clinical presentation in out-patients with acute community-acquired pneumonia].
Mayaud C; Fartoukh M; Prigent H; Parrot A; Cadranel J
Med Mal Infect; 2006; 36(11-12):625-35. PubMed ID: 17084571
[TBL] [Abstract][Full Text] [Related]
58. [CAPNETZ. The competence network for community-acquired pneumonia (CAP)].
Suttorp N; Welte T; Marre R; Stenger S; Pletz M; Rupp J; Schütte H; Rohde G;
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Apr; 59(4):475-81. PubMed ID: 26984399
[TBL] [Abstract][Full Text] [Related]
59. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine.
Goldbart AD; Leibovitz E; Porat N; Givon-Lavi N; Drukmann I; Tal A; Greenberg D
Scand J Infect Dis; 2009; 41(3):182-7. PubMed ID: 19117244
[TBL] [Abstract][Full Text] [Related]
60. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study.
Ramírez JA;
Semin Respir Crit Care Med; 2005 Dec; 26(6):543-52. PubMed ID: 16388426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
